These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2512049)

  • 21. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1990 Mar; 34(3):487-8. PubMed ID: 2110438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro activity of cefpirome compared with that of other agents.
    Raizes EG; Cantey JR
    J Antimicrob Chemother; 1988 Feb; 21(2):177-81. PubMed ID: 3129388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations.
    Gradelski E; Fung-Tomc J; Huczko E; Kessler RE
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():75-80. PubMed ID: 8150769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against Pseudomonas aeruginosa.
    Ozbek B; Otuk G
    Chemotherapy; 2009; 55(6):446-50. PubMed ID: 19996590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Verapamil-tobramycin synergy in Pseudomonas cepacia but not Pseudomonas aeruginosa in vitro.
    Cohn RC; Rudzienski L; Putnam RW
    Chemotherapy; 1995; 41(5):330-3. PubMed ID: 8521733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model.
    Cappelletty DM
    Antimicrob Agents Chemother; 1999 Jan; 43(1):129-33. PubMed ID: 9869577
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria.
    Fung-Tomc J; Huczko E; Kolek B; Thater C; Kessler RE
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2652-4. PubMed ID: 1810203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa.
    Madaras-Kelly KJ; Moody J; Larsson A; Baeker Hovde L; Rotschafer JC
    Chemotherapy; 1997; 43(2):108-17. PubMed ID: 9084919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance].
    Canis F; Cavallo JD; Husson MO
    Pathol Biol (Paris); 1997 May; 45(5):420-3. PubMed ID: 9296096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
    Chin JN; Jones RN; Sader HS; Savage PB; Rybak MJ
    J Antimicrob Chemother; 2008 Feb; 61(2):365-70. PubMed ID: 18079128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia.
    Gold R; Jin E; Levison H; Isles A; Fleming PC
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():331-6. PubMed ID: 6352638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp.
    Mayer I; Nagy E
    J Antimicrob Chemother; 1999 May; 43(5):651-7. PubMed ID: 10382886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. L-658,310, a new injectable cephalosporin. II. In vitro and in vivo interactions between L-658,310 and various aminoglycosides or ciprofloxacin versus clinical isolates of Pseudomonas aeruginosa.
    Valiant ME; Gilfillan EC; Gadebusch HH; Pelak BA
    J Antibiot (Tokyo); 1989 May; 42(5):807-14. PubMed ID: 2498278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of Pseudomonas aeruginosa persistence during treatment with broad-spectrum cephalosporins of lung infections in patients with cystic fibrosis.
    Schryvers AB; Ogunariwo J; Chamberland S; Godfrey AJ; Rabin HR; Bryan LE
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1438-9. PubMed ID: 3118800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis.
    Cohn RC; Jacobs M; Aronoff SC
    Antimicrob Agents Chemother; 1988 Mar; 32(3):395-6. PubMed ID: 3364958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
    Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):917-9. PubMed ID: 2512141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro.
    Tunney MM; Scott EM
    J Microbiol Methods; 2004 Apr; 57(1):107-14. PubMed ID: 15003693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria.
    Petrova G; Strateva T; Miteva D; Lazova S; Perenovska P
    J Infect Dev Ctries; 2016 Nov; 10(11):1265-1267. PubMed ID: 27886041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.